“Very commonly these children have a very, very, sick brain and they epilepsy is not just causing them to seize but is also interfering with their ability to learn to walk or to read or to have good sleep,” Dr. Ingram said. … read more at: http://www.kait8.com/2018/11/11/epilepsy-patients-testing-out-new-marijuana-based-medication/

by

“Very commonly these children have a very, very, sick brain and they epilepsy is not just causing them to seize but is also interfering with their ability to learn to walk or to read or to have good sleep,” Dr. Ingram said. … read more at: https://www.wmcactionnews5.com/2018/11/09/epilepsy-patients-testing-out-new-marijuana-based-medication/

by

Better Information For Better Health Mr. Boise added, ” With this FDA Orphan Drug application, the most significant benefit is to the patients with Huntington’s disease since our development process can be advanced quickly to address their unmet needs. ” RESTON, Va. (PRWEB) November 09, 2018 MMJ International… read more at: https://www.prweb.com/releases/2018/11/prweb15907893.htm

by

Researchers at the UM School of Pharmacy are teaming with UMMC to conduct the clinical trial of a marijuana-derived anti-seizure drug. Over four years after Gov. Phil Bryant signed Harper Grace’s Law, allowing clinical trials of a specific marijuana-derived drug, the University of Mississippi Medical Center announced Thursday that those trials had begun. Several agencies, […]

by

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic RD partner, SciCann Therapeutics (“SciCann”). The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the […]

by

DEVON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2018 and provided an overview of recent operational highlights. “The momentum we established in the first half of 2018 […]

by

A clinical trial of a new drug derived from marijuana to treat seizures in children has received approval, and patients are receiving the medication, according to the physician directing it. Following a rigorous review process, the trial is being conducted by the University of Mississippi Medical Center and the UM School of Pharmacy on UMMC’s […]

by

On Wednesday, Revive Therapeutics Ltd., a tiny Toronto-based company that trades on the OTCQB as RVVTF, revealed that it secured FDA orphan drug designation for cannabidiol (CBD) to prevent hepatic ischemia and reperfusion injury resulting from solid organ transplantation. Under license from South Carolina Research Foundation, a unit of the University of South Carolina, Revive […]

by

Companies left, and right are creating products infused with cannabis to deliver to a market that is rapidly growing. More and more people today are witnessing the health benefits of the drug and are supporting the legislation. One stock that could soon be shining on Wall Street is International Spirits and Beverage Group Inc. (OTC: […]

by

TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the […]

by

Save Article In this market news, FSD Pharma Inc. (CSE:HUGE), one of the Canadian marijuana stocks, said it has launched a pilot clinical study for the treatment of irritable bowel syndrome (IBS) SmallCapPower | November 7, 2018: FSD Pharma Inc. (CSE:HUGE), one of the Canadian cannabis stocks, announced recently the launch of a pilot clinical […]

by